cor2ed
engage checkpoint medical linkedin twitter
bg

Antibody-drug conjugates in urothelial cancer

Antibody-drug conjugates in urothelial cancer

Prof. Sandy Srinivas

Prof. Sandy Srinivas takes a look at antibody-drug conjugates (ADCs) in urothelial cancer.
Image of Sandy Srinivas
Prof. Sandy Srinivas

Medical Oncologist

Stanford University Medical Center

United States (US)

preview next

time Expert View | open 5 min

I agree that this educational programme:

Was valuable to me:

1/3

Prof. Sandy Srinivas takes a look at antibody-drug conjugates (ADCs) in urothelial cancer, in particular the first-in-class drug, Enfortumab Vedotin, and the pivotal trial resulting in registration together with promising data in combination with checkpoint inhibitors as well as another ADC, Sacituzumab Govitecan, which targets Trop-2. Prof. Srinivas also discusses the development of ADCs for other GU tumour types.

Other programmes of interest